Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  trastuzumab
Find trials that include:  Any drugs shown
Results 1-25 of 60 for your search:
Start Over
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MM-302-02-02-03, NCI-2014-02093, NCT02213744
Radiation Therapy, Paclitaxel, and Carboplatin with or without Trastuzumab in Treating Patients with Esophageal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: RTOG 1010, NCI-2011-02601, CDR0000683717, NCT01196390
A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BO28408, NCI-2014-01818, NCT02131064
Trastuzumab in Treating Leptomeningeal Metastases in Patients with HER2-Positive Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 10C03, NCI-2011-00110, STU00040150, NCT01325207
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
Phase: Phase II, Phase I
Type: Treatment
Age: not specified
Trial IDs: TED12414, NCI-2012-02198, 2011-006140-78, U1111-1124-1403, NCT01587040
Vaccine Therapy with or without Polysaccharide-K in Treating Patients with Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 7866, NCI-2013-01377, 135, 7866/135, NCT01922921
Ruxolitinib Phosphate and Trastuzumab in Treating Patients with Metastatic HER2-Positive Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAM1906, NCI-2014-02015, NCT02066532
Gemcitabine Hydrochloride, Trastuzumab, and Pertuzumab in Treating Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17656, NCI-2014-01935, 14.01.0062, 280513, Genentech ML28939, ML28939, NCT02139358
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: KD019-204, NCI-2014-02048, NCT02154529
Vaccine Therapy, Trastuzumab, and Vinorelbine Tartrate in Treating Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 0418, NCI-2013-00498, UNC-LCCC-0418, NCT00266110
Everolimus with or without Trastuzumab in Treating Patients with Hormone-Refractory Metastatic Breast Cancer Receiving Hormone Therapy
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: WCI1524-08/H4459S, NCI-2011-03381, WCI1524-08, NCT00912340
Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Stage IV Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J0947, NCI-2010-02004, NA_00024527, JHOC-J0947, GENENTECH-JHOC-J0947, NCT00971737
Control or Extended Lapatinib Ditosylate and Trastuzumab With or Without Goserelin Acetate or Letrozole in Treating Patients With HER2-Positive Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TBCRC 023, NCI-2012-01766, H-25846, NCT00999804
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 097517, NCI-2015-00014, NCT01042379
Lapatinib Ditosylate and Trastuzumab in Treating Older Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: 10112, NCI-2011-00116, 105241, 115357, NCT01273610
Everolimus, Trastuzumab, and Vinorelbine Tartrate in Treating Patients With Progressive HER2-Positive Breast Cancer and Brain Metastases
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and over
Trial IDs: LCCC 1025, NCI-2013-01079, 11-0242, NCT01305941
Carboplatin and Paclitaxel With or Without Trastuzumab in Treating Patients With HER2-Positive Stage III-IV or Recurrent Uterine Cancer
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 1012007786, NCI-2013-00894, NCT01367002
Start Over